HealthLeaders-InterStudy and Fingertip Formulary find that fixed dosed combination agents and novel antihypertensives are expected to face tougher formulary restrictions. According to the new Formulary Forum report entitled Formulary Advantages in Hypertension: Past and Future Shifts in Tier Placement of Angiotensin II Receptor Antagonists, Single Pill Fixed-Dose Combinations and Novel Agents, step therapy restrictions are becoming more common in commercial health plans across all classes of antihypertensives, suggesting fixed dosed combination agents and novel antihypertensives will face less access on Tier 2 on commercial health plans.

The report notes that although the number of commercial health plans placing step restrictions on angiotensin II receptor antagonists is relatively stable, a growing number of covered lives are subject to a step therapy restriction. Meanwhile, the number of commercial health plans placing prior authorization restrictions on antihypertensives has decreased over the past year.

"By and large, more agents are subject to prior authorization restrictions with more commercial health plans than are subject to step therapy restrictions, but we are seeing step therapy restrictions becoming increasingly common," said Michael Malecki, Ph.D., product manager, Formulary Forum. "The changing landscape of formulary controls in the hypertension market means that managed care marketing and sales analytics groups must track this newly-important performance metric."

About Formulary Advantages in Hypertension: Past and Future Shifts in Tier Placement of Angiotensin II Receptor Antagonists, Single Pill Fixed-Dose Combinations and Novel Agents

The new Formulary Forum report is based on a survey of 50 pharmacy directors who control national, regional and state-level managed care organizations, as well as historical formulary data from Fingertip Formulary. Answers were segmented by type of plan to illustrate variances in strategy by size of plan. The easy-to-use PowerPoint format allows easy visualization of data and easy incorporation of material into presentations.

About Fingertip Formulary

Fingertip Formulary (www.FingertipFormulary.com), the leading provider of access to and insight into formulary data in the United States, offers comprehensive formulary data covering commercial, Medicaid, Medicare and PBM plans, among others. The company offers a variety of unique data and marketing solutions for the pharmaceutical industry, consultants and healthcare providers that provide access to and insight into formulary data. Fingertip Formulary is a Decision Resources, Inc. company.

About HealthLeaders-InterStudy

HealthLeaders-InterStudy, a Decision Resources, Inc. company, is the authoritative source for managed care data, analysis and news. For more information, please visit www.HL-ISY.com.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Both HealthLeaders-InterStudy and Fingertip Formulary are Decision Resources, Inc. companies. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

First Call Analyst:
FCMN Contact:

SOURCE: HealthLeaders-InterStudy

CONTACT: Lisa Osgood, HealthLeaders-InterStudy, +1-781-296-2606,
losgood@hl-isy.com; Elizabeth Marshall, Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

For Bipolar Depression, Surveyed Experts Indicate That Current and Emerging Therapies Have No Advantage Over Seroquel in Decreasing the Severity of Symptoms

View Now